Northern Trust’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $47.9M | Buy |
1,245,751
+46,451
| +4% | +$1.72M | 0.01% | 1120 |
|
|
2025
Q4 | $42.6M | Buy |
1,199,300
+17,635
| +1% | +$496K | 0.01% | 1208 |
|
|
2025
Q3 | $17M | Buy |
1,181,665
+247,170
| +26% | +$2.93M | ﹤0.01% | 1801 |
|
|
2025
Q2 | $6.71M | Buy |
934,495
+54,658
| +6% | +$303K | ﹤0.01% | 2305 |
|
|
2025
Q1 | $5.27M | Sell |
879,837
-32,876
| -4% | -$258K | ﹤0.01% | 2384 |
|
|
2024
Q4 | $7.12M | Buy |
912,713
+65,415
| +8% | +$652K | ﹤0.01% | 2317 |
|
|
2024
Q3 | $9.15M | Buy |
847,298
+127,846
| +18% | +$1.24M | ﹤0.01% | 2117 |
|
|
2024
Q2 | $6.06M | Buy |
719,452
+4,358
| +0.6% | +$33.1K | ﹤0.01% | 2282 |
|
|
2024
Q1 | $4.81M | Buy |
715,094
+1,507
| +0.2% | +$9.32K | ﹤0.01% | 2479 |
|
|
2023
Q4 | $4.2M | Buy |
713,587
+725
| +0.1% | +$5.56K | ﹤0.01% | 2606 |
|
|
2023
Q3 | $6.95M | Buy |
712,862
+98,532
| +16% | +$1.17M | ﹤0.01% | 2237 |
|
|
2023
Q2 | $7.27M | Buy |
614,330
+63,402
| +12% | +$727K | ﹤0.01% | 2270 |
|
|
2023
Q1 | $5.94M | Buy |
550,928
+8,193
| +2% | +$105K | ﹤0.01% | 2347 |
|
|
2022
Q4 | $6.27M | Buy |
542,735
+7,132
| +1% | +$88.4K | ﹤0.01% | 2338 |
|
|
2022
Q3 | $7.99M | Buy |
535,603
+179,678
| +50% | +$2.46M | ﹤0.01% | 2153 |
|
|
2022
Q2 | $3.21M | Buy |
355,925
+61,741
| +21% | +$421K | ﹤0.01% | 2797 |
|
|
2022
Q1 | $2.2M | Sell |
294,184
-15,064
| -5% | -$105K | ﹤0.01% | 3048 |
|
|
2021
Q4 | $2.65M | Sell |
309,248
-21,202
| -6% | -$184K | ﹤0.01% | 3077 |
|
|
2021
Q3 | $2.78M | Sell |
330,450
-11,544
| -3% | -$88.5K | ﹤0.01% | 3102 |
|
|
2021
Q2 | $2.77M | Buy |
341,994
+281,768
| +468% | +$2.38M | ﹤0.01% | 3198 |
|
|
2021
Q1 | $529K | Buy |
60,226
+6,746
| +13% | +$64.9K | ﹤0.01% | 3803 |
|
|
2020
Q4 | $601K | Buy |
53,480
+46,552
| +672% | +$511K | ﹤0.01% | 3674 |
|
|
2020
Q3 | $65K | Buy |
6,928
+1,537
| +29% | +$16K | ﹤0.01% | 4060 |
|
|
2020
Q2 | $10K | Hold |
5,391
| – | – | ﹤0.01% | 4214 |
|
|
2020
Q1 | $9K | Buy |
5,391
+2,461
| +84% | +$6.84K | ﹤0.01% | 4157 |
|
|
2019
Q4 | $8K | Hold |
2,930
| – | – | ﹤0.01% | 4206 |
|
|
2019
Q3 | $17K | Sell |
2,930
-40,893
| -93% | -$332K | ﹤0.01% | 4166 |
|
|
2019
Q2 | $459K | Sell |
43,823
-3,187
| -7% | -$42.4K | ﹤0.01% | 3578 |
|
|
2019
Q1 | $826K | Buy |
47,010
+2,350
| +5% | +$40.2K | ﹤0.01% | 3425 |
|
|
2018
Q4 | $786K | Buy |
44,660
+33,836
| +313% | +$1M | ﹤0.01% | 3437 |
|
|
2018
Q3 | $446K | Buy |
10,824
+16
| +0.1% | +$902 | ﹤0.01% | 3664 |
|
|
2018
Q2 | $620K | Buy |
+10,808
| New | +$520K | ﹤0.01% | 3550 |
|
Other funds holding COGT
DM
VPM
VCM
FFM
RI
TCM
Northern Trust's COGT Position: Q1 2026 in Review
Northern Trust increased its Cogent Biosciences (COGT) stake by 3.9% in Q1 2026, buying an estimated $1.72M and bringing the position to 1,245,751 shares worth $47.9M. The position accounts for 0.01% of the portfolio, ranked #1120.
Northern Trust first reported a position in COGT in Q2 2018 and has held it in 32 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.
- Northern Trust held 1,245,751 shares of Cogent Biosciences worth $47.9M as of Q1 2026.
- Northern Trust bought 46,451 Cogent Biosciences shares in Q1 2026, an estimated $1.72M.
- Cogent Biosciences made up 0.01% of Northern Trust's portfolio in Q1 2026, its #1120 holding.
- Northern Trust first reported a position in Cogent Biosciences in Q2 2018 and has held it in 32 quarters since.
- 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.